Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $128.00

Kodiak Sciences (NASDAQ:KOD – Get Free Report) had its price target increased by stock analysts at JPMorgan Chase & Co. from $124.00 to $128.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 30.99% from the stock’s previous close.

Several other research analysts have also weighed in on KOD. HC Wainwright upped their target price on shares of Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Jefferies Financial Group reissued a “buy” rating and set a $112.00 price target on shares of Kodiak Sciences in a research note on Monday, September 28th. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. UBS Group raised their price objective on Kodiak Sciences from $120.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, November 13th. Finally, Weiss Ratings cut Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $117.86.

Check Out Our Latest Stock Report on KOD

Kodiak Sciences Stock Down 0.1%

Shares of Kodiak Sciences stock traded down $0.10 during trading on Thursday, reaching $97.72. The company’s stock had a trading volume of 250,521 shares, compared to its average volume of 1,112,736. Kodiak Sciences has a 12-month low of $19.25 and a 12-month high of $112.79. The company has a market capitalization of $6.39 billion, a P/E ratio of -23.98 and a beta of 2.02. The business has a 50 day moving average price of $80.54 and a 200-day moving average price of $46.86.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.01. Research analysts predict that Kodiak Sciences will post -4.05 EPS for the current fiscal year.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 86,432 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were acquired at an average price of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director directly owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. The trade was a 0.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 2,188,845 shares of company stock valued at $181,326,862 in the last quarter. 44.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP lifted its holdings in Kodiak Sciences by 9.7% in the 3rd quarter. Baker BROS. Advisors LP now owns 21,860,941 shares of the company’s stock valued at $2,072,417,000 after purchasing an additional 1,941,755 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Kodiak Sciences during the third quarter worth about $27,204,000. Bellevue Group AG acquired a new position in shares of Kodiak Sciences in the third quarter valued at approximately $43,648,000. Cetera Investment Advisers acquired a new position in shares of Kodiak Sciences in the third quarter valued at approximately $231,000. Finally, Marshall Wace LLP acquired a new position in shares of Kodiak Sciences in the third quarter valued at approximately $9,584,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

See Also

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.